for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Medknow Publishers   (Total: 426 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 426 Journals sorted alphabetically
Acta Medica Intl.     Open Access   (SJR: 0.101, CiteScore: 0)
Advanced Arab Academy of Audio-Vestibulogy J.     Open Access  
Advanced Biomedical Research     Open Access  
Advances in Human Biology     Open Access   (Followers: 4)
Advances in Skeletal Muscle Function Assessment     Open Access  
African J. for Infertility and Assisted Conception     Open Access  
African J. of Medical and Health Sciences     Open Access   (Followers: 3)
African J. of Paediatric Surgery     Open Access   (Followers: 7, SJR: 0.25, CiteScore: 1)
African J. of Trauma     Open Access   (Followers: 1)
Ain-Shams J. of Anaesthesiology     Open Access   (Followers: 3)
Al-Azhar Assiut Medical J.     Open Access   (Followers: 2)
Al-Basar Intl. J. of Ophthalmology     Open Access   (Followers: 1)
Alexandria J. of Pediatrics     Open Access   (Followers: 1)
Ancient Science of Life     Open Access   (Followers: 5)
Anesthesia : Essays and Researches     Open Access   (Followers: 10)
Annals of African Medicine     Open Access   (Followers: 2, SJR: 0.258, CiteScore: 1)
Annals of Bioanthropology     Open Access   (Followers: 4)
Annals of Cardiac Anaesthesia     Open Access   (Followers: 14, SJR: 0.308, CiteScore: 1)
Annals of Indian Academy of Neurology     Open Access   (Followers: 3, SJR: 0.434, CiteScore: 1)
Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery     Open Access  
Annals of Indian Psychiatry     Open Access  
Annals of Maxillofacial Surgery     Open Access   (Followers: 6)
Annals of Medical and Health Sciences Research     Open Access   (Followers: 7)
Annals of Nigerian Medicine     Open Access   (Followers: 1)
Annals of Pediatric Cardiology     Open Access   (Followers: 12, SJR: 0.352, CiteScore: 1)
Annals of Saudi Medicine     Open Access   (SJR: 0.238, CiteScore: 1)
Annals of Thoracic Medicine     Open Access   (Followers: 6, SJR: 0.524, CiteScore: 1)
Annals of Tropical Medicine and Public Health     Open Access   (Followers: 13, SJR: 0.152, CiteScore: 0)
Annals of Tropical Pathology     Open Access  
Apollo Medicine     Open Access  
APOS Trends in Orthodontics     Open Access   (Followers: 1)
Arab J. of Interventional Radiology     Open Access   (Followers: 1)
Archives of Cardiovascular Imaging     Open Access   (Followers: 2, SJR: 0.187, CiteScore: 0)
Archives of Intl. Surgery     Open Access   (Followers: 10, SJR: 0.302, CiteScore: 1)
Archives of Medicine and Health Sciences     Open Access   (Followers: 3)
Archives of Medicine and Surgery     Open Access  
Archives of Pharmacy Practice     Open Access   (Followers: 10, SJR: 0.102, CiteScore: 0)
Archives of Trauma Research     Open Access   (Followers: 3, SJR: 0.37, CiteScore: 2)
Asia Pacific J. of Clinical Trials : Nervous System Diseases     Open Access  
Asia-Pacific J. of Oncology Nursing     Open Access   (Followers: 5)
Asian J. of Andrology     Open Access   (Followers: 1, SJR: 0.856, CiteScore: 2)
Asian J. of Neurosurgery     Open Access   (Followers: 2)
Asian J. of Oncology     Open Access   (Followers: 2)
Asian J. of Transfusion Science     Open Access   (Followers: 1, SJR: 0.35, CiteScore: 1)
Asian Pacific J. of Reproduction     Open Access   (SJR: 0.227, CiteScore: 1)
Asian Pacific J. of Tropical Biomedicine     Open Access   (Followers: 2, SJR: 0.491, CiteScore: 2)
Asian Pacific J. of Tropical Medicine     Open Access   (Followers: 1, SJR: 0.561, CiteScore: 2)
Astrocyte     Open Access  
Avicenna J. of Medicine     Open Access   (Followers: 1)
AYU : An international quarterly journal of research in Ayurveda     Open Access   (Followers: 6)
Benha Medical J.     Open Access  
Biomedical and Biotechnology Research J.     Open Access  
BLDE University J. of Health Sciences     Open Access  
Brain Circulation     Open Access   (Followers: 1)
Bulletin of Faculty of Physical Therapy     Open Access   (Followers: 1)
Canadian J. of Rural Medicine     Full-text available via subscription   (SJR: 0.202, CiteScore: 0)
Cancer Translational Medicine     Open Access   (Followers: 2)
Cardiology Plus     Open Access   (Followers: 1)
Chinese Medical J.     Open Access   (Followers: 10, SJR: 0.52, CiteScore: 1)
CHRISMED J. of Health and Research     Open Access   (Followers: 2)
Clinical Cancer Investigation J.     Open Access  
Clinical Dermatology Review     Open Access   (Followers: 4)
Clinical Trials in Degenerative Diseases     Open Access  
Clinical Trials in Orthopedic Disorders     Open Access  
Community Acquired Infection     Open Access  
Conservation and Society     Open Access   (Followers: 8, SJR: 0.811, CiteScore: 2)
Contemporary Clinical Dentistry     Open Access   (Followers: 4, SJR: 0.353, CiteScore: 1)
Current Medical Issues     Open Access   (Followers: 1)
CytoJ.     Open Access   (Followers: 2, SJR: 0.543, CiteScore: 1)
Delta J. of Ophthalmology     Open Access  
Dental Hypotheses     Open Access   (Followers: 4, SJR: 0.152, CiteScore: 0)
Dental Research J.     Open Access   (Followers: 13, SJR: 0.416, CiteScore: 1)
Dentistry and Medical Research     Open Access  
Digital Medicine     Open Access  
Drug Development and Therapeutics     Open Access  
Education for Health     Open Access   (Followers: 6, SJR: 0.242, CiteScore: 0)
Egyptian J. of Bronchology     Open Access  
Egyptian J. of Cardiothoracic Anesthesia     Open Access  
Egyptian J. of Cataract and Refractive Surgery     Open Access   (Followers: 1, SJR: 1.799, CiteScore: 2)
Egyptian J. of Chest Diseases and Tuberculosis     Open Access   (Followers: 3, SJR: 0.155, CiteScore: 0)
Egyptian J. of Dermatology and Venerology     Open Access   (Followers: 1)
Egyptian J. of Haematology     Open Access   (Followers: 1)
Egyptian J. of Internal Medicine     Open Access   (Followers: 1)
Egyptian J. of Obesity, Diabetes and Endocrinology     Open Access   (Followers: 1)
Egyptian J. of Otolaryngology     Open Access   (Followers: 2)
Egyptian J. of Psychiatry     Open Access   (Followers: 1)
Egyptian J. of Surgery     Open Access   (Followers: 1)
Egyptian Nursing J.     Open Access  
Egyptian Orthopaedic J.     Open Access   (Followers: 2)
Egyptian Pharmaceutical J.     Open Access   (Followers: 3)
Egyptian Retina J.     Open Access  
Egyptian Rheumatology and Rehabilitation     Open Access   (Followers: 2)
Endodontology     Open Access  
Endoscopic Ultrasound     Open Access   (SJR: 0.822, CiteScore: 2)
Environmental Disease     Open Access   (Followers: 3)
Eurasian J. of Pulmonology     Open Access  
European J. of Dentistry     Open Access   (Followers: 3, SJR: 0.749, CiteScore: 2)
European J. of General Dentistry     Open Access   (Followers: 1, SJR: 0.12, CiteScore: 0)
European J. of Prosthodontics     Open Access   (Followers: 4)
European J. of Psychology and Educational Studies     Open Access   (Followers: 11, SJR: 0.113, CiteScore: 0)
Fertility Science and Research     Open Access  
Formosan J. of Surgery     Open Access   (SJR: 0.112, CiteScore: 0)
Genome Integrity     Open Access   (Followers: 2, SJR: 0.153, CiteScore: 0)
Glioma     Open Access  
Global J. of Transfusion Medicine     Open Access   (Followers: 1)
Gynecology and Minimally Invasive Therapy     Open Access   (SJR: 0.311, CiteScore: 1)
Hamdan Medical J.     Open Access  
Heart and Mind     Open Access  
Heart India     Open Access   (Followers: 1)
Heart Views     Open Access   (Followers: 2)
Hepatitis B Annual     Open Access   (Followers: 3)
Ibnosina J. of Medicine and Biomedical Sciences     Open Access  
IJS Short Reports     Open Access  
Imam J. of Applied Sciences     Open Access  
Indian Dermatology Online J.     Open Access   (Followers: 3)
Indian J. of Allergy, Asthma and Immunology     Open Access   (Followers: 1)
Indian J. of Anaesthesia     Open Access   (Followers: 7, SJR: 0.478, CiteScore: 1)
Indian J. of Burns     Open Access   (Followers: 1)
Indian J. of Cancer     Open Access   (Followers: 1, SJR: 0.361, CiteScore: 1)
Indian J. of Cerebral Palsy     Open Access   (Followers: 1)
Indian J. of Community Medicine     Open Access   (Followers: 2, SJR: 0.37, CiteScore: 1)
Indian J. of Dental Research     Open Access   (Followers: 5, SJR: 0.266, CiteScore: 1)
Indian J. of Dental Sciences     Open Access  
Indian J. of Dentistry     Open Access   (Followers: 1)
Indian J. of Dermatology     Open Access   (Followers: 2, SJR: 0.468, CiteScore: 1)
Indian J. of Dermatology, Venereology and Leprology     Open Access   (Followers: 4, SJR: 0.445, CiteScore: 1)
Indian J. of Dermatopathology and Diagnostic Dermatology     Open Access  
Indian J. of Drugs in Dermatology     Open Access   (Followers: 1, SJR: 0.791, CiteScore: 1)
Indian J. of Endocrinology and Metabolism     Open Access   (Followers: 4, SJR: 0.568, CiteScore: 1)
Indian J. of Health Sciences and Biomedical Research KLEU     Open Access   (Followers: 2)
Indian J. of Medical and Paediatric Oncology     Open Access   (SJR: 0.425, CiteScore: 1)
Indian J. of Medical Microbiology     Open Access   (Followers: 2, SJR: 0.503, CiteScore: 1)
Indian J. of Medical Research     Open Access   (Followers: 4, SJR: 0.656, CiteScore: 1)
Indian J. of Medical Sciences     Open Access   (Followers: 2, SJR: 0.102, CiteScore: 0)
Indian J. of Multidisciplinary Dentistry     Open Access   (Followers: 1)
Indian J. of Nephrology     Open Access   (Followers: 2, SJR: 0.347, CiteScore: 1)
Indian J. of Nuclear Medicine     Open Access   (Followers: 2, SJR: 0.23, CiteScore: 0)
Indian J. of Occupational and Environmental Medicine     Open Access   (Followers: 3, SJR: 0.225, CiteScore: 1)
Indian J. of Ophthalmology     Open Access   (Followers: 4, SJR: 0.498, CiteScore: 1)
Indian J. of Oral Health and Research     Open Access  
Indian J. of Oral Sciences     Open Access   (Followers: 1)
Indian J. of Orthopaedics     Open Access   (Followers: 8, SJR: 0.392, CiteScore: 1)
Indian J. of Otology     Open Access   (Followers: 1, SJR: 0.199, CiteScore: 0)
Indian J. of Paediatric Dermatology     Open Access   (Followers: 2)
Indian J. of Pain     Open Access   (Followers: 2)
Indian J. of Palliative Care     Open Access   (Followers: 6, SJR: 0.454, CiteScore: 1)
Indian J. of Pathology and Microbiology     Open Access   (Followers: 3, SJR: 0.276, CiteScore: 1)
Indian J. of Pharmacology     Open Access   (SJR: 0.412, CiteScore: 1)
Indian J. of Plastic Surgery     Open Access   (Followers: 13, SJR: 0.311, CiteScore: 0)
Indian J. of Psychiatry     Open Access   (Followers: 2, SJR: 0.408, CiteScore: 1)
Indian J. of Psychological Medicine     Open Access   (SJR: 0.368, CiteScore: 1)
Indian J. of Public Health     Open Access   (Followers: 1)
Indian J. of Radiology and Imaging     Open Access   (Followers: 4)
Indian J. of Research in Homoeopathy     Open Access  
Indian J. of Respiratory Care     Open Access  
Indian J. of Rheumatology     Open Access   (Followers: 1, SJR: 0.119, CiteScore: 0)
Indian J. of Sexually Transmitted Diseases and AIDS     Open Access   (Followers: 2, SJR: 0.34, CiteScore: 0)
Indian J. of Social Psychiatry     Open Access   (Followers: 1)
Indian J. of Transplantation     Open Access  
Indian J. of Urology     Open Access   (Followers: 4, SJR: 0.434, CiteScore: 1)
Indian J. of Vascular and Endovascular Surgery     Open Access   (Followers: 2)
Indian Spine J.     Open Access  
Industrial Psychiatry J.     Open Access   (Followers: 2)
Intervention     Open Access   (Followers: 1)
Intl. Archives of Health Sciences     Open Access  
Intl. J. of Abdominal Wall and Hernia Surgery     Open Access   (Followers: 1)
Intl. J. of Academic Medicine     Open Access  
Intl. J. of Advanced Medical and Health Research     Open Access  
Intl. J. of Applied and Basic Medical Research     Open Access  
Intl. J. of Clinical and Experimental Physiology     Open Access   (Followers: 1)
Intl. J. of Clinicopathological Correlation     Open Access   (Followers: 1)
Intl. J. of Community Dentistry     Open Access  
Intl. J. of Critical Illness and Injury Science     Open Access   (Followers: 1, SJR: 0.192, CiteScore: 0)
Intl. J. of Educational and Psychological Researches     Open Access   (Followers: 4)
Intl. J. of Environmental Health Engineering     Open Access   (Followers: 1)
Intl. J. of Forensic Odontology     Open Access   (Followers: 1)
Intl. J. of Green Pharmacy     Open Access   (Followers: 5, SJR: 0.142, CiteScore: 0)
Intl. J. of Growth Factors and Stem Cells in Dentistry     Open Access  
Intl. J. of Health & Allied Sciences     Open Access   (Followers: 3)
Intl. J. of Health System and Disaster Management     Open Access   (Followers: 3)
Intl. J. of Heart Rhythm     Open Access  
Intl. J. of Medicine and Public Health     Open Access   (Followers: 6)
Intl. J. of Mycobacteriology     Open Access   (SJR: 0.535, CiteScore: 1)
Intl. J. of Noncommunicable Diseases     Open Access  
Intl. J. of Nutrition, Pharmacology, Neurological Diseases     Open Access   (Followers: 4, SJR: 0.17, CiteScore: 0)
Intl. J. of Oral Health Sciences     Open Access   (Followers: 3)
Intl. J. of Orofacial Biology     Open Access   (Followers: 1)
Intl. J. of Orofacial Research     Open Access   (Followers: 2)
Intl. J. of Orthodontic Rehabilitation     Open Access   (Followers: 1)
Intl. J. of Pedodontic Rehabilitation     Open Access  
Intl. J. of Pharmaceutical Investigation     Open Access   (Followers: 2)
Intl. J. of Preventive Medicine     Open Access   (Followers: 1, SJR: 0.623, CiteScore: 1)
Intl. J. of Shoulder Surgery     Open Access   (Followers: 5, SJR: 0.653, CiteScore: 1)
Intl. J. of the Cardiovascular Academy     Open Access   (SJR: 0.105, CiteScore: 0)
Intl. J. of Trichology     Open Access   (SJR: 0.4, CiteScore: 1)
Intl. J. of Yoga     Open Access   (Followers: 15)
Intl. J. of Yoga : Philosophy, Psychology and Parapsychology     Open Access   (Followers: 6)
Iranian J. of Nursing and Midwifery Research     Open Access   (Followers: 3)
Iraqi J. of Hematology     Open Access  
J. of Academy of Medical Sciences     Open Access  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Indian Journal of Drugs in Dermatology
Journal Prestige (SJR): 0.791
Citation Impact (citeScore): 1
Number of Followers: 1  

  This is an Open Access Journal Open Access journal
ISSN (Print) 2455-3972
Published by Medknow Publishers Homepage  [426 journals]
  • Biologics in psoriasis: Indian experience

    • Authors: Shrichand G Parasramani, Jisha Pillai
      Pages: 1 - 5
      Abstract: Shrichand G Parasramani, Jisha Pillai
      Indian Journal of Drugs in Dermatology 2019 5(1):1-5

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):1-5
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_33_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Janus Kinase Inhibitors in Dermatology

    • Authors: Aditya Kumar Bubna
      Pages: 6 - 13
      Abstract: Aditya Kumar Bubna
      Indian Journal of Drugs in Dermatology 2019 5(1):6-13
      Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts. This review throws light on JAK inhibitors and their role in dermatologic diseases.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):6-13
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_38_18
      Issue No: Vol. 5, No. 1 (2019)
       
  • Real-life efficacy and safety of secukinumab: A single-center,
           retrospective observational study with 52-week follow-up

    • Authors: Shekhar Neema, S Radhakrishnan, Sehdev Singh, Biju Vasudevan, Manas Chatterjee
      Pages: 14 - 18
      Abstract: Shekhar Neema, S Radhakrishnan, Sehdev Singh, Biju Vasudevan, Manas Chatterjee
      Indian Journal of Drugs in Dermatology 2019 5(1):14-18
      Background: Secukinumab is a fully human monoclonal antibody against interleukin-17. Phase III trials have shown encouraging results in chronic plaque psoriasis. The real-life data for safety and efficacy of secukinumab are limited. Methodology: This was a retrospective, single-center, observational study conducted in a tertiary care center of East India between January 2016 and December 2017. Patients with chronic plaque psoriasis who were initiated on injection secukinumab during the study period and completed 52 weeks of observation period were included in the study. Analysis was performed using SPSS version 25. Results: Twenty patients were recruited in the study. Mean age of the patients was 46 years and mean duration of disease was 11 years. Eleven (55%) patients were biologic experienced and Nine (45%) patients were biologic naïve. Mean Psoriasis Area and Severity Index (PASI) score at baseline was 17.05 (±6.7). Fifteen (75%) patients achieved PASI75 at 4 weeks. Seventeen (85%) patients achieved PASI75, 13 (65%) achieved PASI90, and 10 (50%) patients achieved PASI100 at 12 weeks. Eighteen (90%), 10 (50%), and 7 (35%) patients maintained PASI75, PASI90, and PASI100 response, respectively, at the end of 52 weeks. Adverse effects were seen in 6 (30%) patients over 52 weeks. Drug discontinuation was required because of severe exacerbation of eczema and recalcitrant vulvovaginal candidiasis in one patient each. Conclusion: Secukinumab is an effective drug for the management of chronic plaque psoriasis even in patients who have previously been treated with systemic drugs and other biologics; however, adverse effects are more common as compared to what trial data suggest. Limitations of Study: Small sample size and retrospective study design are main limitations of the study. Strength of Study: This is first real-life data with 52 weeks follow up from India.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):14-18
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_37_18
      Issue No: Vol. 5, No. 1 (2019)
       
  • A comparative study between topical adapalene (0.1%) versus a
           combination of topical adapalene (0.1%) and intense pulsed light
           therapy in the treatment of inflammatory and noninflammatory facial acne
           vulgaris: A split-face randomized controlled trial

    • Authors: Shah Karan, Jadhav Vikrant, Gugle Anil
      Pages: 19 - 25
      Abstract: Shah Karan, Jadhav Vikrant, Gugle Anil
      Indian Journal of Drugs in Dermatology 2019 5(1):19-25
      Introduction: Acne vulgaris is a common dermatological disorder encountered in dermatology practice. Various treatment modalities are available for acne. Lasers and light-based therapies are also gaining popularity with good clinical results. The choice of treatment depends on the type and severity of acne. Aims:(1) To evaluate the efficacy and safety of topical adapalene (0.1%) gel in facial acne vulgaris. (2) To evaluate the efficacy and safety of topical adapalene (0.1%) gel in combination with intense pulsed light (IPL) in facial acne vulgaris. (3) To compare the above results. Materials and Methods: A total of 50 patients with facial acne were included. IPL device equipped with an acne treatment filter emitting light between 430 and 1200 nm was used. Adapalene 0.1% in gel form was used. One side of the face was treated with plain adapalene gel and another side with a combination of daily application of adapalene, with fortnightly exposure of IPL. A total of four sittings of IPL at the interval of 15 days were given. Final evaluation was done 2 weeks after the last session of IPL. Results: On adapalene + IPL-treated side, statistically significant reduction in comedones started from the 2nd visit,P < 0.05. On the 6th visit, there was statistically significant difference in mean comedones (P < 0.05) between two sides. After the study (9 weeks), the mean reduction in inflammatory lesion was 69.98% for adapalene-treated side and 79.92% for combination therapy. Conclusion: IPL therapy with 430–1200 nm wavelength filter is an effective adjuvant therapy when used with adapalene 0.1 gel. It gives an additional benefit in the treatment of acne. We can avoid systemic antibiotics and retinoids using adapalene and IPL combination in mild-to-moderate acne.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):19-25
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_28_18
      Issue No: Vol. 5, No. 1 (2019)
       
  • Oral ranitidine: A promising novel therapeutic option in molluscum
           contagiosum in children

    • Authors: Pooja Agarwal, Bhushan Madke, Priyanka Bodar
      Pages: 26 - 29
      Abstract: Pooja Agarwal, Bhushan Madke, Priyanka Bodar
      Indian Journal of Drugs in Dermatology 2019 5(1):26-29
      Background: Molluscum contagiosum(MC) is one of the most common cutaneous viral infection observed in children. Though, it is benign and self-limiting, treatment is often sought for cosmetic reasons. Existing invasive therapeutic modalities are generally not well tolerated in children because of pain and risk of scarring. Immunomodulatory potential of cimetidine is well established. We thus extrapolated the same to ranitidine and conducted this study. Aim: To assess the efficacy of oral ranitidine in treatment of molluscum contagiosum in immunocompetent children. Methods: A multicentre longitudinal study was conducted in the dermatology departments of tertiary care hospitals in Ahmedabad and Wardha, India over a period of 4 months. 24 children with MC were included. Oral ranitidine was started in dose of 5 mg/kg/day in two divided doses for 8 weeks. Follow up was done very 15 days and changes in number and size of lesions were noted. Results: Mean age of patients was 5.08 years. 19 patients completed the study. 15 patients had improvement in the lesions at the end of 8 weeks while 4 patients did not show any improvement. Complete clearance was seen in 14 patients(73.6%) and 1 patient had decrease in size of the lesions without change in the number. Mean duration of complete clearance of lesion was 6.5 weeks. Conclusion: Oral ranitidine may be considered as a safe and effective alternative therapeutic option in widespread MC in immunocompetent children where invasive painful procedures are less desirable.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):26-29
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_41_18
      Issue No: Vol. 5, No. 1 (2019)
       
  • Successful Treatment of Pyogenic Granuloma with Sclerotherapy

    • Authors: Neelima Bansal, Vasudha A Belgaumkar, Ravindranth B Chavan, Bhavana Ravindra Doshi
      Pages: 30 - 33
      Abstract: Neelima Bansal, Vasudha A Belgaumkar, Ravindranth B Chavan, Bhavana Ravindra Doshi
      Indian Journal of Drugs in Dermatology 2019 5(1):30-33
      Pyogenic granuloma (PG) is a common benign vascular proliferation that usually occurs on the skin and mucosa. Various treatment options exist in literature with no clear consensus. Our objective was to evaluate the efficacy and safety of sclerotherapy (sodium tetradecyl sulfate [STS]) in PG. This case series included 15 patients of PG, treated with intralesional injection of the STS (3%, 30 mg/ml) solution. All patients showed complete resolution of PG, without any major complication or recurrence during a 6-month follow-up period.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):30-33
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_6_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Sorafenib-Induced Cutaneous Toxicities: Four Different Presentations

    • Authors: Pooja Bains, Saurabh Sharma
      Pages: 34 - 37
      Abstract: Pooja Bains, Saurabh Sharma
      Indian Journal of Drugs in Dermatology 2019 5(1):34-37
      Sorafenib is a multikinase inhibitor which is used in the treatment of hepatocellular carcinoma and renal cell carcinoma. The cutaneous toxicities due to sorafenib can affect the daily activities of patients, resulting in interruption or dose modification of therapy. We report four cases of adverse cutaneous effects of sorafenib along with their management. The cases represent the wide spectrum of sorafenib cutaneous toxicities from mild to severe.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):34-37
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_36_18
      Issue No: Vol. 5, No. 1 (2019)
       
  • Thalidomide-induced leukocytoclastic vasculitis in leprosy

    • Authors: Vasudha Abhijit Belgaumkar, Pallavi Prataprao Patil, Ravindranath Brahmadeo Chavan, Prernaa R Suryataley
      Pages: 38 - 41
      Abstract: Vasudha Abhijit Belgaumkar, Pallavi Prataprao Patil, Ravindranath Brahmadeo Chavan, Prernaa R Suryataley
      Indian Journal of Drugs in Dermatology 2019 5(1):38-41
      Thalidomide has become the gold standard for the treatment of erythema nodosum leprosum (ENL) within a few decades of its serendipitous discovery for this condition. It has also demonstrated efficacy in dermatoses such as recalcitrant oral aphthae, prurigo nodularis, and pyoderma gangrenosum. Despite a good safety profile, thalidomide is known to cause side effects such as sedation, constipation, peripheral neuropathy, and thromboembolism. Although rare and anecdotal, adverse cutaneous drug reactions (ACDRs) have been reported. Both thalidomide and its newer analogs have been implicated for maculopapular, urticaria-angioedema, Steven–Johnson-like, toxic epidermal necrolysis, and acneiform eruptions. Only a few cases of leukocytoclastic vasculitis (LCV) occurring in patients of multiple myeloma on this drug have been described till date. However, this unusual presentation of ACDR due to thalidomide in leprosy has not been hitherto documented. Herein, we describe a patient of lepromatous leprosy with ENL who developed thalidomide-induced LCV and discuss myriad aspects such as immunopathogenesis with emphasis on the possible role of various cytokines such as interleukin (IL)-2, IL-6, IL-12, and tumor necrosis factor-alpha.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):38-41
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_14_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • &#8220;PRIDE&#8221; Complex: A Report of Two Cases

    • Authors: Shashank Krishna Agrawal, Bhagyashree Babanrao Supekar, Vaishali Wankhade, Rajesh Pratap Singh
      Pages: 42 - 45
      Abstract: Shashank Krishna Agrawal, Bhagyashree Babanrao Supekar, Vaishali Wankhade, Rajesh Pratap Singh
      Indian Journal of Drugs in Dermatology 2019 5(1):42-45
      Epidermal growth factor receptor inhibitors are currently widely used for the treatment of nonsmall cell lung cancer and head-and-neck malignancy. These are associated with constellation of cutaneous reactions termed as PRIDE complex which comprises papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness. We report two cases of PRIDE complex, diagnosed clinically and histopathologically in patients of nonsmall cell carcinoma of the lung being treated with erlotinib and gefitinib.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):42-45
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_8_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Drug-induced Henoch-Schonlein purpura with severe gastrointestinal
           involvement

    • Authors: Nibedita Dixit, Chinmoy Raj, Debasmita Behera, Maitreyee Panda
      Pages: 46 - 48
      Abstract: Nibedita Dixit, Chinmoy Raj, Debasmita Behera, Maitreyee Panda
      Indian Journal of Drugs in Dermatology 2019 5(1):46-48

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):46-48
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_24_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Drug-Induced Hypersensitivity Syndrome to Leflunomide

    • Authors: Dhanashree Santosh Bhide, Kiran Chartrabhuj Ardad, Jaismeen Kaur Arora
      Pages: 48 - 50
      Abstract: Dhanashree Santosh Bhide, Kiran Chartrabhuj Ardad, Jaismeen Kaur Arora
      Indian Journal of Drugs in Dermatology 2019 5(1):48-50

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):48-50
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_22_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • A first case of late-onset imatinib mesylate-induced lichenoid drug
           eruption

    • Authors: Farhana I Khan, Girishkumar R Ambade, A G. Krishna Greeshma, Anand J Asia
      Pages: 51 - 54
      Abstract: Farhana I Khan, Girishkumar R Ambade, A G. Krishna Greeshma, Anand J Asia
      Indian Journal of Drugs in Dermatology 2019 5(1):51-54

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):51-54
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_15_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Delayed-onset serum sickness due to rituximab in pemphigus vulgaris

    • Authors: Ajay Deshpande
      Pages: 54 - 57
      Abstract: Ajay Deshpande
      Indian Journal of Drugs in Dermatology 2019 5(1):54-57

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):54-57
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_5_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Desloratadine induced headache: Are we noticing or missing it?

    • Authors: Harsimran Chawla, Mohammad Rafi, Chaitanya Namdeo, Chhaya Goyal
      Pages: 57 - 58
      Abstract: Harsimran Chawla, Mohammad Rafi, Chaitanya Namdeo, Chhaya Goyal
      Indian Journal of Drugs in Dermatology 2019 5(1):57-58

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):57-58
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_18_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Potassium iodide: A prodigy in the treatment of subcutaneous zygomycosis

    • Authors: Peela Nalini, Seethalakshmi Ganga Vellaisamy, Navakumar Manickam, Kannan Gopalan
      Pages: 59 - 62
      Abstract: Peela Nalini, Seethalakshmi Ganga Vellaisamy, Navakumar Manickam, Kannan Gopalan
      Indian Journal of Drugs in Dermatology 2019 5(1):59-62

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):59-62
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_10_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Viva voce on apremilast

    • Authors: Uday S Khopkar, Kinjal Deepak Rambhia
      Pages: 63 - 65
      Abstract: Uday S Khopkar, Kinjal Deepak Rambhia
      Indian Journal of Drugs in Dermatology 2019 5(1):63-65

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):63-65
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_36_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • Managing a side effect: Cyclophosphamide-induced hemorrhagic cystitis

    • Authors: Bhavana Ravindra Doshi, Vijaya Veeranna Sajjan, BS Manjunathswamy
      Pages: 66 - 71
      Abstract: Bhavana Ravindra Doshi, Vijaya Veeranna Sajjan, BS Manjunathswamy
      Indian Journal of Drugs in Dermatology 2019 5(1):66-71
      Cyclophosphamide is a nonphase-specific cytotoxic agent that can kill cells at any phase of the cell cycle. The drug is metabolized by hepatic cytochrome P450 microsomal enzymes, which results in the formation of the active metabolites phosphoramide mustard and acrolein. It is the acrolein which is responsible for hemorrhagic cystitis as a complication of cyclophosphamide therapy. An early diagnosis and prompt management holds the key in its management.
      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):66-71
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_31_19
      Issue No: Vol. 5, No. 1 (2019)
       
  • News from regulatory corner: Safety communication and recent drug
           approvals

    • Authors: Manasi Shirolikar
      Pages: 72 - 74
      Abstract: Manasi Shirolikar
      Indian Journal of Drugs in Dermatology 2019 5(1):72-74

      Citation: Indian Journal of Drugs in Dermatology 2019 5(1):72-74
      PubDate: Mon,22 Jul 2019
      DOI: 10.4103/ijdd.ijdd_28_19
      Issue No: Vol. 5, No. 1 (2019)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 34.236.170.48
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-